期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2-丙基-4-[(1-羟基-1-甲基)乙基]-1H-咪唑-5-羧酸乙酯的合成 被引量：5

Synthesis of ethyl 4-[(1-hydroxy-1-methyl)ethyl]-2-propyl-1H-imidazole-5-carboxylate
在线阅读 下载PDF
导出
摘要 用正丁酸与邻苯二胺为原料,在微波照射下缩合成2-丙基苯并咪唑,再氧化开环制得2-丙基咪唑二羧酸,再经酯化、Gringard反应制得抗高血压药物奥美沙坦的关键中间体2-丙基-4-[(1-羟基-1-甲基)乙基]-1H-咪唑-5-羧酸乙酯,总收率32.2%。 　Ethyl 4-[（1-hydroxy-1-methyl）ethyl]-2-propyl-1H-imidazole-5-carboxylate,the key intermediate of Olmesartan,was synthesized from butanoic acid and o-phenylenediamine via condensation under microwave-irradiation,oxidation,esterification and the Gringard reaction.The overall yield of target product was 32.2%.
作者 王尊元 张萍 梁美好 沈正荣
机构地区 浙江省医学科学院药物研究所
出处 《化学试剂》 CAS CSCD 北大核心 2007年第11期679-680,共2页 Chemical Reagents
基金 浙江省科技厅面上项目(2005F13G5250019)
关键词 2-丙基-4-[(1-羟基-1-甲基)乙基]-1H-咪唑-5-羧酸乙酯 奥美沙坦 中间体 合成 ethyl 4-[（1-hydroxy-1-methyl）ethyl]-2-propyl-1H-imidazole-5-carboxylate Olmesartan intermediate synthesis
分类号 O624.12 [理学—有机化学]
  • 相关文献

参考文献7

  • 1GARDNER S F, FRANKA A M. Olmesartan medoxomil:the seventh angiotension receptor antagonist [ J ].Ann. Pharmacother. ,2003,37(1) :99-105.
  • 2封宇飞,雷静,吕俊玲,刘志鹤,李金娥.新一代血管紧张素受体阻断剂奥美沙坦酯[J].中国新药杂志,2003,12(7):520-523. 被引量：23
  • 3周燕萍.Benicar[J].中国新药杂志,2004,13(3):276-277. 被引量：2
  • 4YANAGISAWA H, SHIMOJI Y. 1-Biphenylimidazole derivatives, their preparation and. their therapeutic use: EP, 0 503 785[P]. 1992-09-16.
  • 5YANAGISAWA H, AME-MIYA Y, KANAZAKI T, et al. Nonpeptide angiotensin receptor antagonists : synthesis, biological activities, and structure-activity relationships of imidazole-5- carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds[J]. J. Med. Chem. , 1996,39(1) :323-338.
  • 6虞心红,汤建,温新民,毛庆华,沈永嘉.抗高血压新药奥美沙坦的合成[J].华东理工大学学报（自然科学版）,2005,31(2):189-192. 被引量：9
  • 7吕维忠,刘波,游新奎.2-丙基苯并咪唑的无溶剂微波合成及其表征[J].化学试剂,2005,27(6):375-376. 被引量：6

二级参考文献28

  • 1Neutel JM, Elliott WJ,Izzo JL, et al.Antihypertenslve efficacy of olmesartan medoxomil, a new angiotensin Ⅱ receptorantagonist, as assessed by ambulatory blood pressure measurements[J].J Clin Hypertens (Greenwich), 2002,4(5) : 325 - 331.
  • 2Uchler K, Laels P, Witte PU,et al .Antihypertensive efficacy of CS-866,a novel angiotensin-Ⅱ antagiotenist[abstraet no. 293].J Hypertension, 1997,15(Suppl 4) :S185.
  • 3Timmemans PB, Wong PC, Chiu AT, et al. Angiotensin Ⅱ receptors and angiotensin Ⅱ receptor antagonists[ J ]. Pharmacol Rev, 1993,45 (2) : 205.
  • 4BENICAR^TM tablets (olmesartan medoxomil).http://www.rxlist.com/cgi/generic/benicar _ cp. htm[EB/OL]. 2003 - 06 - 16.
  • 5Sehwocho LR, Masonson HN.Pharmacokinetics of CS-866, a new angiotensin Ⅱ receptor blocker, in healthy subjects[ J ].J Clin Pharmacol,2001,41(5) :515 - 527.
  • 6Kawaratani T, Puchler K, Laeis P, et al.Steady state pharmacokinetics of CS-866, a novel angqotensin Ⅱ receptor antagonist in elderly and young hypertensive patients[ abstract no. 9 ] [J]. J Hum Hypertens, 1999,13(Suppl 3) :S4.
  • 7Laeis P, Puchler K, yon Bergmann K.A comparative pharmacokinetic,safety and tolerability trail of the oral angiotensin Ⅱ antagonist olmesartan medoxomil in subjects with varying degrees of renal impairment and in health volunteers[abstract no.P2.147][J].J Hypertension,2001,19(Suppl 2):S145.
  • 8Bergmann K, Laeis P, Puchler K, et al. Olmesartan medoxornil:influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil[ J ]. J Hypertens,2001,19(Suppl1) :S33- S40.
  • 9Puchler K, Laeis P, Kawaratani T, et al. The effect of the combination,of the oral angiotensive Ⅱ-antagiotenist CS-866 and warfarin on pharmacodynamics, pharmacokinetics and safety in healthy, male subjects[abstract no.271][J].J Hypertension,1999,17(Suppl 3) : S275.
  • 10Laeis P,Puchler K,Kirch W.The effect of the oral angiotensive Ⅱ -antagiotenist Olmesartan medoxomil on the safety, tolerability and pharmacokinetics of digoxin in the healthy,male subjects[abstract no. 179] [J].J Hypertension ,2001,19(Suppl 2) :S154.

共引文献36

同被引文献43

  • 1徐彩丽,袁华,喻宗沅.奥美沙坦酯的研究进展[J].化学与生物工程,2005,22(4):7-8. 被引量：9
  • 2虞心红,汤建,温新民,毛庆华,沈永嘉.抗高血压新药奥美沙坦的合成[J].华东理工大学学报（自然科学版）,2005,31(2):189-192. 被引量：9
  • 3吴泰志,刘晓华,张福利,谢美华.抗高血压药奥美沙坦酯合成新路线和相关杂质的研究[J].药学学报,2006,41(6):537-543. 被引量：14
  • 4Yanagisawa H, Amemiya Y, Kanazaki T, et al. Nonpeptide angiotensin Ⅱ receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole- 5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds [J]. JMed Chem, 1996, 39 (1) : 323-338.
  • 5Yanagisawa H, Shimoji Y, Fujimoto K, et al. 1-Biphenylimidazole derivatives, their preparation and their therapeutic use: EP, 0503785 [P]. 1992-09-16.
  • 6Zupanoic S, Pecavar A, Vrbinc M, et al. Process for the preparation ofolmesartan medoxomil: WO, 2007017135 [P]. 2007-02-15.
  • 7周宜遂,刘慧,张涛.奥美沙坦制备的新方法:中国,1510035[P].2004-07-07.
  • 8何其林,耿玉先.一种奥美沙坦酯的制备方法:中国,1680335[P].2005-10-12.
  • 9Yanagisawa H, Fujimoto K, Amemiya Y, et al. Angiensin Ⅱ antagonist 1-biphenylmethylimidazole compounds and their therapeutic use: US, 5616599 [P]. 1997-04-01.
  • 10Koguro K, Oga T, Toktmaga N. et al. Process for preparation of 5-substituted tetrazoles: EP 0796852 [P]. 1997-09-24.

引证文献5

二级引证文献10

化学试剂
2007年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部